Isoschaftoside
Based on 1 publication(s) in Google Scholar
Isoschaftoside, a C-glycosylflavonoid from Desmodium uncinatum root exudate, can inhibit the growth of germinated S. hermonthica radicles. Isoschaftoside reduces reactive oxygen species (ROS) and induces proliferation in senescent cells. Isoschaftoside activates autophagy. Isoschaftoside can be used for anti-tumor, anti-inflammatory, antioxidant, antihypertensive, hepatoprotective and nematicidal study.
For research use only. We do not sell to patients.
- Purity : 99.95%
- CAS No.: 52012-29-0
- Formula: C26H28O14
- Molecular Weight:564.49
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Isoschaftoside
MoreAll Parasite Isoforms
More
Biological Activity
Description
In Vitro
Isoschaftoside (4 μM, 12 days) suppresses ROS by reducing the expression of RAC2 and LINC00294 in senescent fibroblasts[1].
Isoschaftoside (0.25-4 μM, 12 days) significantly increases cell proliferation in senescent fibroblasts[1].
Isoschaftoside (1 μM, 12 days) significantly increases mitochondrial membrane potential (MMP), induces metabolic changes that restore mitochondrial function and reduces dependence on glycolysis in senescent fibroblasts[1].
Isoschaftoside (1 μM, 12 days) reduces DNA damage and fragmentation, activates the autophagy system to clear senescent fibroblasts, reduces the expression of inflammatory factors in senescent fibroblasts[1].
Isoschaftoside (20-600 μg/mL) possesses strong nematicidal activity against M. incognita (LC50 = 323.09 μg/mL)[2].
Isoschaftoside (1-500 μM, 24 h) reduces lipid deposition via activating autophagy flux, and suppresses the expression of light-chain 3-II (LC3-II) and SQSTM1/p62 in Palmitic acid (PA) (HY-N0830)-induced autophagy inhibition in HepG2 cells[3].
Isoschaftoside (0.05-2 mg/mL) considerably decreases renal Na+, K+-ATPase activation in basolateral membrane of the proximal tubule from pig kidney[4].
Isoschaftoside (0-1000 μM, 9-24 h) can suppress inflammatory responses in Lipopolysaccharides (HY-D1056) (LPS)-activated microglia[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human dermal fibroblasts
-
Concentration:0.25, 0.5, 1, 2, 4 μM
-
Incubation Time:12 days
-
Result:The increase in cell proliferation rate was most significant at a concentration of 1 μM.
-
Cell Line:human dermal fibroblasts
-
Concentration:1 μM
-
Incubation Time:12 days
-
Result:LC3B was noticeably activated.
Perinuclear mitochondria were reduced.
Showed significantly enhanced levels of autophagy.
Significant reduction in lipofuscin was observed.
-
Cell Line:HepG2 cells
-
Concentration:1, 10, 20, 50, 100, 200, 300, 400, 500 μM
-
Incubation Time:24 h
-
Result:When the concentration was higher than 200 μM, observed significant reductions in LC3-II expression.
Decreased LC3-II and p62 expression in Palmitic acid (PA) (HY-N0830)-induced autophagy.
-
Cell Line:BV2 microglial cells
-
Concentration:200 μM
-
Incubation Time:9 h or 24 h
-
Result:Significantly inhibited Lipopolysaccharides-induced iNOS, TNF-α, IL-1β, and COX2 protein expression.
Significantly reduced the Lipopolysaccharides-induced HIF-1α, HK2, and PFKFB3 expression.
Attenuated Lipopolysaccharides-induced phosphorylation of ERK1/2 and mTOR.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57 mice fed with a high-fat diet (HFD) (4 weeks; male; C57BL/6JGpt)[3]
-
Dosage:20 mg/kg
-
Administration:Intraperitoneal injection (i.p.); daily for 4 weeks
-
Result:Significantly reduced the body weight and body size of the high-fat diet mice compared with the model group.
Reduced the visceral fat weight of high-fat diet mice.
Significantly attenuated hepatic lipid accumulation induced by a high-fat diet and decreased the number of intracellular lipid droplets and hepatocyte balloons.
Reversed the damage to liver function and the elevation of blood glucose caused by a high-fat diet.
The expression level of p62 and LC3-II was significantly lower than that in the HFD group.
Chemical Information
-
CAS No. 52012-29-0
-
Appearance Solid
-
Molecular Weight 564.49
-
Formula C26H28O14
-
Color Light yellow to yellow
-
SMILES
O=C1C=C(C2=CC=C(O)C=C2)OC3=C([C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO)O4)O)O)O)C(O)=C([C@H]5[C@@H]([C@H]([C@H](CO5)O)O)O)C(O)=C13
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (177.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.43 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.43 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
-
Senescence-associated β-galactosidase staining
Senescence-associated β-galactosidase staining detects β-galactosidase activity that is histochemically visible at pH 6. 0 in senescent cells, where X-gal cleavage produces an insoluble blue precipitate observable by bright-field microscopy. This activity reflects increased lysosomal β-galactosidase/lysosomal mass rather than a senescence-essential enzyme, because GLB1 depletion or genetic lysosomal β-galactosidase deficiency can abolish SA-β-gal staining while cells still undergo senescence. SA-β-gal was originally reported in senescent but not presenescent fibroblasts and keratinocytes, absent from quiescent fibroblasts and terminally differentiated keratinocytes, and increased with donor age in human skin samples. Because SA-β-gal can also appear in some non-senescent or tissue-specific contexts, interpretation should be paired with experimental controls and, when possible, independent senescence markers.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (288 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lee YH, et al. Identification of Cellular Isoschaftoside-Mediated Anti-Senescence Mechanism in RAC2 and LINC00294. Molecules. 2024 Sep 4;29(17):4182. [Content Brief]
[2]. Du SS, et al. Nematocidal flavone-C-glycosides against the root-knot nematode (Meloidogyne incognita) from Arisaema erubescens tubers. Molecules. 2011 Jun 20;16(6):5079-86. [Content Brief]
[3]. Su Y, et al. Isoschaftoside Reverses Nonalcoholic Fatty Liver Disease via Activating Autophagy In Vivo and In Vitro. Evid Based Complement Alternat Med. 2022 Jun 27;2022:2122563. [Content Brief]
[5]. Guan S, et al. Isoschaftoside Inhibits Lipopolysaccharide-Induced Inflammation in Microglia through Regulation of HIF-1α-Mediated Metabolic Reprogramming. Evid Based Complement Alternat Med. 2022 Nov 23;2022:5227335. [Content Brief]
[6]. Hooper AM, et al. Isoschaftoside, a C-glycosylflavonoid from Desmodium uncinatum root exudate, is an allelochemical against the development of Striga. Phytochemistry. 2010 Jun;71(8-9):904-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7715 mL | 8.8576 mL | 17.7151 mL | 44.2878 mL |
| 5 mM | 0.3543 mL | 1.7715 mL | 3.5430 mL | 8.8576 mL | |
| 10 mM | 0.1772 mL | 0.8858 mL | 1.7715 mL | 4.4288 mL | |
| 15 mM | 0.1181 mL | 0.5905 mL | 1.1810 mL | 2.9525 mL | |
| 20 mM | 0.0886 mL | 0.4429 mL | 0.8858 mL | 2.2144 mL | |
| 25 mM | 0.0709 mL | 0.3543 mL | 0.7086 mL | 1.7715 mL | |
| 30 mM | 0.0591 mL | 0.2953 mL | 0.5905 mL | 1.4763 mL | |
| 40 mM | 0.0443 mL | 0.2214 mL | 0.4429 mL | 1.1072 mL | |
| 50 mM | 0.0354 mL | 0.1772 mL | 0.3543 mL | 0.8858 mL | |
| 60 mM | 0.0295 mL | 0.1476 mL | 0.2953 mL | 0.7381 mL | |
| 80 mM | 0.0221 mL | 0.1107 mL | 0.2214 mL | 0.5536 mL | |
| 100 mM | 0.0177 mL | 0.0886 mL | 0.1772 mL | 0.4429 mL |
Isoschaftoside Related Classifications
HY-N1458 Related Classifications
Powered by Bioz